Oliceridine + Placebo + Morphine
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Pain
Conditions
Acute Pain
Trial Timeline
May 1, 2016 → Jan 1, 2017
NCT ID
NCT02815709About Oliceridine + Placebo + Morphine
Oliceridine + Placebo + Morphine is a phase 3 stage product being developed by Trevena for Acute Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02815709. Target conditions include Acute Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02815709 | Phase 3 | Completed |
| NCT02820324 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Pain